Beyond Pegylated Interferon-Alpha: New Treatments for Hepatitis Delta.
Antiviral Agents
/ administration & dosage
Clinical Trials, Phase II as Topic
Clinical Trials, Phase III as Topic
Coinfection
/ drug therapy
Drug-Related Side Effects and Adverse Reactions
/ epidemiology
Hepatitis B, Chronic
/ drug therapy
Hepatitis D
/ drug therapy
Hepatitis Delta Virus
/ drug effects
Humans
Interferon-alpha
/ administration & dosage
Lipopeptides
/ administration & dosage
Nucleic Acids
/ administration & dosage
Piperidines
/ administration & dosage
Polymers
/ administration & dosage
Pyridines
/ administration & dosage
Recurrence
Treatment Outcome
Bulevirtide
Hepatitis B virus/hepatitis D (delta) virus coinfection
Lonafarnib
Myrcludex B
Pegylated interferon-lambda
REP-2139-Ca
Journal
AIDS reviews
ISSN: 1698-6997
Titre abrégé: AIDS Rev
Pays: Spain
ID NLM: 101134876
Informations de publication
Date de publication:
2019
2019
Historique:
entrez:
19
9
2019
pubmed:
19
9
2019
medline:
15
1
2020
Statut:
ppublish
Résumé
Persistent coinfection with the hepatitis B/D viruses (HDV) represents the most severe form of viral hepatitis. Hepatitis D often leads to liver cirrhosis, hepatic decompensation, and hepatocellular carcinoma. The current treatment options are limited as only pegylated interferon-alpha (PEG-IFNa) has efficacy against HDV. However, treatment response is still unsatisfactory with 25-40% HDV RNA suppression after 1-2 years. In addition, late HDV RNA relapses have been described during long-term follow-up. Fortunately, new treatment options for patients with chronic hepatitis delta are now on the horizon. The hepatocyte entry inhibitor bulevirtide (formerly myrcludex B) and the farnesyl transferase inhibitor lonafarnib are currently explored in patients with chronic hepatitis delta in Phase 3 clinical studies. The nucleic acid inhibitor REP-2139-Ca and PEG-IFN-lambda are studied in Phase 2 trials. We here summarize data on the efficacy of these new antiviral drugs and the existing safety data on the treatment of HDV infection.
Identifiants
pubmed: 31532397
doi: 10.24875/AIDSRev.19000080
doi:
Substances chimiques
Antiviral Agents
0
Interferon-alpha
0
Lipopeptides
0
Nucleic Acids
0
Piperidines
0
Polymers
0
Pyridines
0
REP 2139
0
myrcludex-B
0
lonafarnib
IOW153004F
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
126-134Informations de copyright
Copyright: © 2019 Permanyer.